Somewhat Positive News Coverage Somewhat Unlikely to Affect Synageva Biopharma Corp (GEVA) Stock Price
News stories about Synageva Biopharma Corp (NASDAQ:GEVA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synageva Biopharma Corp earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.9469100588783 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Synageva Biopharma Corp (NASDAQ GEVA) remained flat at $238.60 during mid-day trading on Thursday. The stock has a 50-day moving average of $215.15 and a 200 day moving average of $131.31. Synageva Biopharma Corp has a 1-year low of $60.19 and a 1-year high of $239.20.
About Synageva Biopharma Corp
Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency).
Receive News & Ratings for Synageva Biopharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synageva Biopharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.